GNI Group (JP:2160) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GNI Group Ltd. has announced that their subsidiary GYRE Pharmaceuticals’ new drug, Avatrombopag Maleate Tablets, for treating thrombocytopenia in chronic liver disease patients, has been approved by China’s National Medical Products Administration. This addition expands the company’s portfolio, which includes treatments for rare diseases, although it is expected to have a minor impact on the fiscal year’s consolidated financial results.
For further insights into JP:2160 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue